Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers by Cohen, Alexander A. et al.
 1 
Construction, characterization, and immunization of nanoparticles that display a 
diverse array of influenza HA trimers 
 
Alexander A. Cohen1, Zhi Yang1, Priyanthi Gnanapragasam1, Susan Ou1, Kim-Marie 
Dam1, Haoqing Wang1,2, Pamela J. Bjorkman1* 
 
1Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, 
CA 91125, USA 
2Present address: Department of Cellular Physiology and Medicine, Stanford University School 
of Medicine, Palo Alto, CA 94305, USA 
*Corresponding author: Email: bjorkman@caltech.edu 
 
Abstract 
Current influenza vaccines do not elicit broadly protective immune responses against multiple 
strains. New strategies to focus the humoral immune response to conserved regions on 
influenza antigens are therefore required for recognition by broadly neutralizing antibodies. It 
has been suggested that B cells with receptors that recognize conserved epitopes would be 
preferentially stimulated through avidity effects by mosaic particles presenting multiple forms of 
a variable antigen. We adapted SpyCatcher-based platforms, AP205 virus-like particles (VLPs) 
and mi3 nanoparticles (NPs), to covalently co-display SpyTagged hemagglutinin (HA) trimers 
from different influenza strains. Here we show successful homotypic and heterotypic 
conjugation of up to 8 different HA trimers to both VLPs and NPs, and demonstrate that 
conjugated particles were stable for several weeks of storage. We characterized the HA-VLPs 
and HA-NPs by cryo-electron tomography to derive the average number of conjugated HAs and 
their separation distances, and compared immunizations of mosaic and homotypic particles in 
wild-type mice. Both types of HA particles elicited strong antibody responses, but the mosaic 
particles did not consistently elicit broader immune responses. We conclude that covalent 
attachment of HAs from currently-circulating influenza strains represents a viable alternative to 
current annual influenza vaccine strategies, but in the absence of further modifications, is 
unlikely to represent a method for making a universal influenza vaccine.  
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Introduction 
Each year, influenza virus infections affect 5-30% of the global population, resulting in millions 
of severe infections and hundreds of thousands of deaths [1]. Yearly epidemics are typically 
caused by the influenza type A, with a smaller number of infections resulting from type B. 
Vaccines can minimize the incidence of severe infections; however, they do not offer complete 
protection and have to be re-administered annually [1, 2]. The lack of complete efficacy of 
current vaccines can be attributed to several reasons. Mainly, the virus undergoes antigenic drift 
in which mutations accumulate over time that can allow the virus to evade the humoral immune 
response [1]. This requires that the vaccine formulation be renewed yearly so that the vaccine 
strains match the circulating strains as closely as possible. Influenza virus also features high 
antigenic diversity resulting in predominantly strain-specific antibody responses and making it 
difficult to recognize conserved regions on the viral antigens [2, 3]. Furthermore, through the 
mechanism of antigenic shift, the RNA segments from strains of different origins can reassort, 
resulting in new strains that are typically the cause of global pandemics that can rapidly circulate 
within an antigenically-naïve population [1]. Altogether, these necessitate the need for a 
universal flu vaccine that could confer protection against a broad swath of antigenically-distinct 
strains, thereby eliminating the need for yearly vaccines and offering protection against 
emergent pandemics.  
 
The antibody response to influenza is primarily directed against the hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins, which appear as a dense array of spikes on the surface of 
the viral particles [3, 4]. The majority of the neutralizing antibody response is against HA, the 
most abundant viral surface glycoprotein and the sialic acid-binding receptor that mediates 
fusion between the viral and host membranes. Influenza HA is a trimer of HA1 and HA2 
heterodimers, which can be subdivided into head and stalk domains [3, 4]. The HA head is 
composed of the middle portion of the HA1 sequence, contains the sialic acid binding site 
responsible for host cell recognition, and features high variability between different 
strains/subtypes. The HA2 subunit along with N- and C-terminal regions of HA1 encodes for the 
more conserved stalk domain, which contains the fusion peptide involved in viral/host cell 
membrane fusion [3, 4]. Antibodies against the immunodominant HA head can be strongly 
neutralizing, but are also strain specific, with the exception of antibodies that recognize the 
receptor binding site [3, 5, 6]. In contrast, the HA stem is immunosubdominant; however, stem 
antibodies are often broader, although generally less potent than anti-head antibodies, and can 
induce antibody-dependent cellular cytotoxicity (ADCC) responses [3, 7-9]. Within the past 10 
years, broadly neutralizing antibodies (bNAbs) against influenza that target conserved HA stem 
epitopes have been discovered, but these antibodies have thus far been difficult to elicit [10]. It 
is generally believed that a broadly protective or “universal” vaccine would require the induction 
of anti-HA stem antibodies. As a result, there have been numerous attempts to refocus the 
immune response to these conserved epitopes [11-16].  
 
One strategy to redirect the antibody response towards invariant epitopes was co-displaying 
influenza HAs from different strains on nanoparticles [16]. The rationale was to display HAs from 
several strains on a multimerized platform, such that any two adjacent HAs have a low 
probability of being identical, thereby giving a competitive advantage to B cells with B cell 
receptors (BCRs) that use avidity effects to recognize conserved epitopes shared between 
different strains. By contrast, BCRs that recognize strain-specific epitopes could not use avidity 
effects to bind adjacent HAs, thus would be less likely to be activated [16]. In this study, 
monomeric HA receptor binding domain (RBD) sequences were fused to an engineered ferritin 
subunit to create self-assembling particles displaying up to eight different RBD sequences 
derived from H1N1 strains at 24 total positions. The elicited humoral immune response in 
injected mice featured high breadth and potency against a panel of diverse H1N1 strains, which 
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was most apparent the larger the number of HAs that were co-displayed, such that the 
simultaneous display of 8 different HAs elicited the greatest breadth in comparison with 
immunization of a cocktail of 8 different homotypic HA nanoparticles. Sorting and isolation of 
memory B cells that were positive for HAs from two different strains further supported the use of 
this strategy for inducing cross-reactive B cells. A logical follow up to this study would be to co-
display HA ectodomain trimers including the stalk and head regions instead of RBD head 
domain monomers, with the hope of eliciting antibody lineages with increased breadth.  
 
We reasoned that co-display of multiple HA trimers on a nanoparticle would be facilitated by a 
system in which soluble HA trimers could be covalently attached to a protein nanoparticle, 
thereby avoiding potential folding problems created by genetically fusing protomers from a 
trimer to a nanoparticle subunit. Numerous NP platforms and coupling strategies have been 
explored for vaccine design [17]. The “plug and display” strategy involves the use of virus-like 
particles (VLPs) or nanoparticles (NPs) fused to a SpyCatcher protein that is covalently 
conjugated to a purified antigen tagged with a short (13-residue) SpyTag [18, 19]. The 
conjugation involves the formation of an isopeptide bond between a lysine from the SpyCatcher 
protein and an aspartate from the Spytag [20]. An advantage of the SpyCatcher-SpyTag system 
is that it allows for the spontaneous irreversible conjugation of a purified antigen with native-like 
post-translational modifications to a scaffold via an incubation of the antigen and scaffold 
proteins under physiological conditions. Available SpyCatcher protein scaffolds are highly 
versatile, coming in different forms that range from a bacteriophage AP205 T=3 icosahedral 
particle (180 SpyCatchers) to a designed dodecahedral NP called mi3 (60 SpyCatchers) [18, 
19]. We recently used AP205 SpyCatcher-VLPs to display SpyTagged trimeric HIV-1 Env 
immunogens and demonstrated priming in immunized mice and non-human primates of B cells 
carrying receptors displaying characteristics of V3-glycan patch-targeting HIV-1 bNAbs [21]. 
 
Here we describe the use of bacteriophage AP205-based SpyCatcher VLPs and engineered 
particle mi3-based SpyCatcher NPs [18, 19] to display a diverse array of HA ectodomain trimers 
from Group 1 and Group 2 influenza A strains. Successful conjugation was demonstrated by 
size-exclusion chromatography, SDS-PAGE, and electron microscopy (EM), with up to eight 
different HA trimers successfully conjugated to make mosaic mi3 particles. The coupled 
particles are stable upon storage for at least one month at 4˚C. Cryo-electron tomography (cryo-
ET) revealed 81-144 conjugated HA trimers per AP205 VLP and 18-24 trimers per mi3 NP, with 
average separation distances between HA trimers ranging from 7-10 nm for the AP205 VLPs to 
12-15 nm for the mi3 NPs. Immunization studies using a mosaic HA-VLP with a valency of two 
(mosaic-2 VLP) were performed in wild-type (wt) mice and compared to mice immunized with a 
mixture of two homotypic VLPs (admix-2 VLPs). Serum ELISAs and neutralization assays from 
immunized mice revealed roughly equivalent breadth and potency for responses to the mosaic-
2 and admix-2 VLPs against a panel of influenza A strains. HA-mi3 NPs were used in a second 
immunization experiment (mosaic-2, -4, or -8 versus admix-2, -4, or -8), which exhibited roughly 
equivalent breadth with an exception in one mouse, suggesting the possibility of greater breadth 
achieved by injection of mosaic particles.  
 
These results demonstrate that SpyCatcher-VLPs and SpyCatcher NPs can be easily used to 
stably display at least 8 different trimeric antigens. Both AP205-HA and mi3-HA particles 
produced strong immune responses in mice. Our biochemical and EM imaging analyses of HA-
VLP and HA-NP particles provide useful characterizations for future efforts to utilize the 
SpyCatcher-SpyTag system for homotypic and heterotypic display of oligomeric antigens.  
 
Results and Discussion 
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Construction of HA-VLPs and HA-NPs. We adapted the AP205 SpyCatcher-VLP platform that 
we had previously used to conjugate a trimeric HIV-1 immunogen [21] as a way to increase the 
intrinsic immunogenicity of HA, mask undesired epitopes located at the bottom of the HA trimer, 
and potentially attach different HA trimers to the same particle. We reasoned that the 
SpyCatcher-VLP platform could be used to display more than one HA by incubating with 
equimolar amounts of different SpyTagged HAs. Although the SpyTagged HAs would be 
conjugated at random to available SpyCatcher proteins, there should be no advantage for the 
conjugation of one HA over another since they all contained the same SpyTag. 
 
We first expressed and purified SpyTagged soluble HA trimers derived from 8 different influenza 
strains (Figure 1A). The constructs for each HA protomer contained HA1 and the HA2 
ectodomain (residue 1-503 H3 numbering) linked to a C-terminal foldon trimerization domain, a 
SpyTag and a 6x-His tag (Figure 1A). The HAs for the SpyCatcher-mi3 conjugations included 
the sialic acid binding knockout mutation Y98F (except for the SpyTagged HAs used to 
conjugate the SpyCatcher-VLPs). SpyTagged HAs including the Y98F substitution purified from 
the supernatants of transiently-transfected mammalian cells were verified to form monodisperse 
and well-behaved trimers by SEC and SDS-PAGE (Figure 1B). We used SpyCatcher-AP205 
VLPs and SpyCatcher-mi3 NPs as conjugation platforms for multivalent display of HA trimers. 
AP205-SpyCatcher VLPs are icosahedral capsids (T=3 symmetry) with 180 copies total, 
therefore 180 Spycatchers for conjugation (Figure 1C). AP205-SpyCatcher VLPs were 
expressed in E. coli and purified via Ni-NTA affinity chromatography followed by SEC (Figure 
1D) [18]. The Spycatcher-AP205-VLPs eluted near the void volume as a single monodisperse 
peak. SpyCatcher-mi3 NPs are a dodecameric engineered scaffold with 60 total subunits, 
therefore 60 conjugation sites (Figure 1E). The SpyCatcher-mi3s were also expressed in E. coli, 
purified by Ni-NTA affinity chromatography followed by SEC, and analyzed with reducing SDS-
PAGE (Figure 1F).  
 
Using the SpyCatcher-AP205 VLPs, we first evaluated coupling of two recombinant HAs, 
A/California/04/09 H1 (CA09-HA) and A/Aichi/02/1968 H3 (Aichi-HA) (chosen to represent two 
strains that would normally be present in an annual influenza vaccine). Conjugations of the 
AP205-Spycatcher VLPs were carried out by room temperature incubation with CA09-HA, Aichi-
HA, or an equimolar mixture of both HAs in a 1.2 molar excess to the VLPs (HA protomer to 
VLP subunit) to prepare CA09-, Aichi-, and mosaic-2 VLPs, respectively (Figure 2A). VLP-
conjugated HA trimers were separated from free trimers by SEC (Figure 2B), and 
successful conjugation of the SpyCatcher VLPs to Aichi-HA, CA09-HA, and both HAs was 
verified by a shift in apparent molecular weight (from 75 kDa to 100 kDa) detected by SDS-
PAGE for HAs conjugated to the VLP subunits (Figure 2B).  
 
Because VLPs conjugated with more than two different HAs tended to precipitate out of solution 
(data not shown), we switched to the SpyCatcher mi3 platform, which is similarly immunogenic 
as the AP205 platform, but has been shown to exhibit improved yields, stability, and uniformity 
[19]. In addition, we modified the SpyTagged HAs to include a receptor binding site mutation, 
Y98F (H3 numbering), to abolish sialic acid binding [22] that could result in interactions of 
aggregation of HAs on neighboring particles. Starting with 8 HAs from influenza group 1 and 
group 2 strains (Figure 1A) with pandemic potential [23], we made mosaic-2, mosaic-4 and 
mosaic-8 mi3 NPs (each with an equal representation of group 1 and group 2 strains) and the 8 
corresponding homotypic HA-conjugated NPs (Figure 2C). Homotypic HA-mi3s were purified via 
SEC, and conjugation was verified by a shift in apparent molecular weight (from 75 kDa to >100 
kDa) detected by SDS-PAGE for HAs conjugated to the mi3 subunits (Figure 2D). Mosaic-mi3 
NPs were purified and analyzed the same way (Figure 2E). Finally, to assess stability of the 
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conjugated NPs, mosaic-NP preps stored for 1 month at 4˚C were analyzed for degradation by 
SEC, revealing little to no free HA trimer for both the mosaic-4 and mosaic-8 NPs.  
 
EM characterization of HA-VLPs and HA-NPs 
Negative-stain EM revealed increased diameters for conjugated VLPs and NPs compared with 
their unconjugated counterparts (Figure 3A). HA-conjugated VLPs were also examined by 
single-particle cryo-EM. 2D class averages of mosaic-2 VLPs showed ordered density for the 
AP205 VLP, but blurred densities for attached HAs (Figure 3B), suggesting variability in trimer 
orientations with respect to the VLP surface.  
 
Since the HA trimer densities could not be reliably interpreted by single-particle cryo-EM, we 
used cryo-ET to derive 3D reconstructions of individual HA-conjugated VLPs and NPs. 
Tomograms (Supplemental Movies 1 and 2) showed particles with average diameters of 60 nm 
(HA-VLPs) and 50 nm (HA-NPs) and revealed densities for individual HA trimers on VLPs and 
NPs. The trimers were separated by distances of ~7-10 nm and ~12-15 nm for VLPs and NPs, 
respectively (measured between the head regions of trimer axes on adjacent HAs). To estimate 
the number of conjugated HA trimers, we counted HA densities in ~3 nm tomographic slices of 
individual HA-VLPs and HA-NPs at their widest diameters, where the symmetries of each type 
of particle predicted a maximum of 20 potential attachment sites. We found 9-16 HA densities 
for conjugated VLPs and 6-8 densities for conjugated NPs, corresponding to occupancies of 45-
80% (VLPs) and 30-40% (NPs). Since AP205 VLPs and mi3 NPs contain 180 or 60 
SpyCatchers, respectively, this translates to ~81-144 conjugated HA trimers per AP205 VLP 
and ~18-24 trimers per mi3 NP.  
 
Immunizations with homotypic- and mosaic-HA-VLPs. Our next goal was to determine 
whether mosaic HA-VLPs induced a more cross-reactive humoral immune response compared 
with a mixture of the corresponding homotypic HA-VLPs. We first immunized one group of four 
mice with mosaic-2 VLPs (presenting CA09 plus Aichi HAs) and a second group of four mice 
with an equal mixture of CA09-VLPs and Aichi-VLPS (admix-2) (Figure 4A). In addition, we 
immunized groups of mice with only Aichi-VLPs or only CA09-VLPs. In all cases, mice were 
primed with equal doses of VLPs plus adjuvant, boosted 2 weeks later without adjuvant, and 
bled weekly for serum analyses.  
 
Serum ELISAs were performed to measure IgG binding to purified HAs from a panel of Group 1 
and Group 2 influenza A strains (Figure 4B). For the Aichi and CA09 HAs presented on the 
VLPs, IgG titers from mosaic-2- and from admix-2-immunized mice were equivalent and similar 
to titers against CA09 HA for CA09-VLP-injected mice and against Aichi HA for Aichi-VLP-
injected mice. Against heterotypic HAs not presented on the VLPs (Viet04, Jp57, WF10, Sh13 
and JX346 HAs), IgG titers were equivalent for both mosaic-2- and admix-2-immunized mice, 
although titers were increased compared with both CA09-VLP- and Aichi-VLP-immunized mice. 
Thus in terms of elicited IgG binding of HAs, it appeared that immunizing with the mosaic-2 
VLPS was no better at inducing cross-reactive binding of HAs from divergent strains than the 
corresponding admixture. However, the mosaic-2 and admix-2 injections seemed to induce 
heterologous breadth that could not be explained by the overlapping immunogenicities of the 
homotypic VLPs.  
 
Neutralizing activity of the serum was determined using in vitro neutralization assays (using live 
viruses for BSL 2 strains and pseudoviruses for BSL 3 strains) against a panel of Group 1 and 
Group 2 influenza A strains (Figure 4C). For the mosaic-2- and admix-2-immunized mice, 
neutralizing titers against homotypic live virus strains (CA09 and Aichi) were consistent with the 
ELISA titers against these strains. Against the Viet04 and JX346 pseudoviruses, neutralization 
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titers are not detectable except from one animal in the admix-2 group. Against the Sh13 
pseudovirus, neutralizing titers for the mosaic-2-immunized mice were higher than for the other 
groups, although the spread in potency was broad and overlapped with the other groups. 
Altogether in terms of neutralization, it appeared that immunizing with the mosaic-2 VLPs may 
have induced antibodies with slightly higher breadth than for the admixture of homotypic VLPs, 
when considered together with the ELISA results, the mosaic-2 VLPs were not better than the 
homotypic VLPs in eliciting breadth.  
 
In order to determine whether mosaic-HA NPs with higher valencies could elicit antibody 
responses with higher breadth, we conducted experiments similar to those described for VLPs 
to compare injections of mosaic-2, -4 and -8 NPs with the corresponding admixtures of 
homotypic NPs (Figure 5A), with a CA09-NP homotypic control, and with unconjugated 
SpyCatcher-NPs. A final boost was performed 5 weeks after the first prime and animals were 
sacrificed 2 weeks later to harvest spleens for B cell analysis. Serum IgG titers from Day 21 and 
Day 49 were measured using ELISAs against a panel of purified HAs from homotypic and 
heterotypic Group 1 and Group 2 strains (Figure 5B) and against unconjugated SpyCatcher-mi3 
NPs. All groups of mice exhibited antibody responses to unconjugated SpyCatcher-mi3, 
suggesting that SpyCatcher and/or NP epitopes are accessible on HA-conjugated particles. 
 
Against HAs from homotypic strains (CA09 and Aichi), the serum from mice immunized with 
both the admix and mosaic NPs featured equivalent titers, with the exception of the admix-4 
mouse group, which responded with overall lower titers and included 2 mice with no responses. 
Against the Viet04 and JX346 HAs (presented on particles with valencies of 4 and 8), the 
response was slightly higher for the mosaic-2 NPs than for the Ca09-mi3 and admix-2 groups, 
whereas the mosaic-4, mosaic-8 and admix-8 groups showed higher titers, although over a 
broad range that included mice with poor responses even against strains of HA that were 
presented on admix-4 NPs. Against the Jp57, JX346, WF10, and HB09 HAs (only present on 
the valency-8 NPs), the admix-8 and mosaic-8 titers were equivalent to each other and the 
highest on average. The titers against heterologous HAs from the CA09-mi3-injected mice were 
similar to titers from mice injected with SpyCatcher-mi3 NPs, with the exception of responses 
against Jp57 HA. Responses to the mosaic-2 NPs were slightly higher than responses against 
admix-2 and CA09-mi3, again except for the recognition of Jp57 HA. One animal in the mosaic-
4 group exhibited high titers against HAs from all strains in comparison to the admix-4 mice, 
with the mosaic-4 responses being on par with responses from the animals immunized with the 
valency-8 NPs. Finally, against HAs from Pe10 and WA79 (not presented on the any of the 
NPs), serum titers were low for most of the injected animals except for some animals from the 
mosaic-4 group (e.g., the animal that exhibited high titers against strains not represented on the 
mosaic-4 NPs), and admix-8- and mosaic-8-immunized mice.  
 
ELISAs were also used to evaluate recognition of CA09-miniHA, a stabilized stem-only 
construct derived from CA09 HA [11] to ask whether there was preferred recognition of stem 
epitopes by the animals immunized with mosaic-NPs. We found that the serum response 
against the CA09 stem was equivalent to responses against the head-containing CA09 HA 
trimer, with the CA09-mi3-immunized mice exhibiting the highest titers (Figure 5B), suggesting 
that the mosaic-NPs did not preferentially elicit anti-stem responses. 
 
ELISA titers determined for serum samples obtained on Day 51 showed similar responses as 
Day 21 titers with a few exceptions. For example, the mosaic-8 NP-immunized mice had lower 
titers with respect to the admix-8 mice against some of the HAs, suggesting that the boosts 
were not consistently resulting in strong immune responses. The mice immunized with the 
mosaic-4 NPs mounted more robust responses, although two of the animals exhibited low titers 
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against all of the strains (as compared with three animals from Day 21). Based on ELISA 
binding results, we did not find strong evidence of increased cross-reactivity induced in animals 
immunized with the mosaic NPs compared with animals injected with the corresponding admix-
NPs of the same valency. However, for the mosaic-4 NP group, one animal repeatedly showed 
high titers of IgG binding to HAs from all strains tested, suggesting that this animal may have 
induced cross-reactive antibodies. The caveat is that the number of animals in this experiment 
was low, so that results from animals that responded poorly to immunogenic challenge lowered 
the average titers, even though cross-reactive antibodies may have been elicited in at least one 
animal in this group.  
 
In vitro neutralization assays were also conducted using Day 51 serum against a panel Group 1 
and Group 2 influenza strains (Figure 5C). For CA09, neutralization titers were consistent with 
the ELISA titers, with Ca09-mi3-immunized mice showing the highest responses. The 
neutralizing response to Aichi also corresponded to the ELISA results. For the two heterotypic 
H1 and H3 HAs (TX91 and WI05 strains), serum from all animals was non-neutralizing, 
suggesting that neutralizing antibodies that cross-react within the H1 and H3 subtypes were not 
induced. For Viet04, Sh13 and NL03, the neutralizing responses were inconclusive and hard to 
interpret due to high background neutralization from the unconjugated mi3 control serum. For 
JX346, titers for the mosiac-2-immunized mice were higher in comparison to the admix-2-
immunized mice, which exhibited no detectable neutralization activity. For mosaic-4-injected 
mice, serum from the same animal shown to bind to most strains by ELISA also showed a high 
neutralizing titer against the JX346 strain that was comparable to titers from the mosaic-8-
immunized mice, which were injected with particles that presented JX346 HA. Overall, it 
appeared that the mosaic-NPs did not offer an advantage compared to corresponding mixtures 
of homotypic particles in induction of neutralizing antibodies, although the mosaic-4 and mosaic-
2 groups included some animals in which some breadth was induced.  
 
B cell responses induced by mosaic- versus homotypic-NP immunizations. In order to 
determine whether cross-reactive B cells were elicited during the immune response to mice 
immunized with the mosaic-NPs, IgG+ B cells from immunized mouse spleens were probed for 
binding to soluble HAs from three different influenza strains using flow cytometry (Figure 6A). 
The percent binding was determined by gating antigen-specific populations to compare 
populations positive for CA09, Viet04, or Aichi HAs alone, and for double-positive populations 
representing B cells that exhibited cross-reactivity (Figure 6B; Supplementary Figure 3). As 
expected, the percent CA09+ population was the largest for the CA09-mi3-immunized mice, 
with the rest of the mosaic and admix groups eliciting a similar proportion of the CA09+ B cells. 
Admix and mosaic groups with valencies of 4 and 8 elicited a similar levels of Viet04+ IgG+ B 
cells, as expected since Viet04 HA was present on these NPs. Interestingly, the mosaic-2-
immunized mice elicited a somewhat lower, but detectable, number of Viet04+ B cells, which 
are not present in the admix-2 and homotypic CA09-mi3 samples. Except for the CA09-mi3-
immunized mice, all animals showed Aichi+ B cells; however, the mosaic-2-immunized mice 
elicited the largest number, consistent with the ELISA and neutralization results (Figure 6A,B). 
Interestingly, very few CA09+/Viet04+ B cells were induced in immunized animals, with the 
exception of one animal in the mosaic-4-immunized group, which also featured a high serum 
IgG and neutralizing response. The CA09-mi3 and admix-8 immunized mice seem to have also 
induced double-positive B cells, although to a smaller extent. CA09+/Aichi+ and Viet04+/Aichi+ 
double-positive B cells were not detected for any of the animals (data not shown).  
 
Taken together, our results suggest that immunizations with mosaic-NPs conjugated with HA 
trimers did not offer a clear advantage in the induction of cross-reactive B cells compared with 
immunization of mixtures of homotypic NPs. However, one animal immunized with the mosaic-4 
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NPs may have induced bona fide cross-reactive B cells that were not only shown to bind to two 
different HAs, but also produced serum that was cross-reactive by ELISA and in vitro 
neutralization with multiple strains of influenza (Figure 5B,C; 6B). Further immunization 
experiments on a larger cohort of animals will be required to determine if this result is 
reproducible in other animals before concluding that mosaic-VLPs induce better recognition of 
conserved HA epitopes. 
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METHODS 
 
Expression and purification of soluble HA trimers. HA ectodomain trimers were expressed 
as shown schematically in Figure 1A with a C-terminal foldon trimerization domain, 13-residue 
SpyTag [20], and a 6x-His (modified from HA constructs in [26] to include a SpyTag). Genes 
corresponding to the modified HA1-HA2 sequences (residues 1-504 H3 numbering) from 
A/Aichi/02/1968 (Aichi; H3), A/Shanghai/1/2013 (SH13; H7), A/Jiangxi-Donghu/346/2013 
JX346; H10), A/swine/HuBei/06/2009 (HB09; H4), A/California/04/2009 (CA09; H1), 
A/Vietnam/1203/ 2004 (Viet04; H5), A/Japan/305/1957 (JP57; H2), and A/guinea fowl/Hong 
Kong/1999 (WF10; H9N2) were subcloned into a pTT5 vector expression vector. Genes 
encoding SpyTagged HAs with a Y98F mutation (H3 numbering) were constructed using site 
directed mutagenesis. HA ectodomain trimer constructs were expressed by transient 
transfection using the Expi293 Expression System (ThermoFisher), and soluble HA trimers were 
purified from transfected cell supernatants by standard Ni-NTA chromatography using a 
prepacked HisTrapTM HP column (GE Healthcare) and SEC using a HiLoad® 16/600 
Superdex® 200 column (GE Healthcare). Proteins were concentrated using a Amicon Ultra 15 
mL 30K concentrator (MilliporeSigma) and stored at 4 °C in 20 mM Tris pH 8.0, 150 mM NaCl, 
0.02% NaN3 (TBS buffer). 
 
HA ectodomain trimers for ELISAs were expressed as above without the 13-residue SpyTag or 
the Y98F substitution. Additional strains only used for ELISA include: A/shearwater/West 
Australia/2576/79 (WA79; H15) and A/flat-faced bat/Peru/033/2010 (Pe10; H18). The CA09-
miniHA construct [11] (construct #4900) was subcloned into a pTT5 vector with a 6x-His tag and 
expressed and purified as described for the HA ectodomain trimers. For flow cytometry 
experiments, an Avi-tag was inserted after the C-termini of the Aichi, Viet04, and CA09 HAs with 
the Y98F substitution. Avi-tagged HAs were expressed and purified as described above and 
biotinylated using the Biotin ligase kit (Avidity) according to the manufacturer’s protocol. 
Biotinylated CA09-HA, Aichi-HA and Viet04-HA were incubated with eBioscienceTM Streptavidin 
APC, Streptavidin PE-eFluor™ 610, or Streptavidin PE (ThermoFisher) overnight at 4oC at a 1:1 
molar ratio of HA trimer to streptavidin subunit.  
 
Expression of SpyCatcher-VLPs and SpyCatcher NPs. pGEN SpyCatcher AP205-CP3 for 
expression of SpyCatcher-VLPS was the kind gift of Dr. Mark Howarth (Oxford University). 
pGEN SpyCatcher AP205-CP3 was transformed into OverExpress™ C41(DE3) E.coli (Sigma). 
Single colonies were picked and inoculated into a 2xYT (Sigma) overnight starter culture and 
then grown in 1L 2xYT media with shaking at 220 rpm at 37˚C until OD 0.5 (A600), after which 
they were induced with 0.42 mM IPTG and grown for 5 hours at 30˚C. Cultures were harvested 
and pellets were frozen in lysis buffer (20mM Tris-HCl pH 7.8, 150mM NaCl, 0.1% Tween 20, 
75 mM imidazole). For producing VLPs for conjugation, pellets were thawed and lysed with a 
cell disruptor in the presence of 2.0 mM PMSF (Sigma). The lysate was spun at 21,000xg for 30 
min, filtered with a 0.2 µm filter, and VLPs were isolated by Ni-NTA chromatography using a 
prepacked HisTrapTM HP column (GE Healthcare). SpyCatcher VLPs were eluted with 2.0 M 
imidazole, 50 mM glycine, 25 mM sodium citrate, 0.1% Tween 20, pH 8.5. Eluted VLPs were 
concentrated using an Amicon Ultra 15 mL 30K concentrator (MilliporeSigma) and further 
purified by SEC using a HiLoad® 16/600 Superdex® 200 (GE Healthcare) column equilibrated 
with 500 mM glycine pH 8, 250 mM sodium citrate, 1% Tween 20. VLPs were then stored at 4°C 
and used for up to 1 month for conjugations. SpyCatcher-VLPs precipitated out of solution over 
time and before use for conjugations, they were either filtered with a 0.2 µm filter or spun down 
at 21,000g for 10 min. 
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The pET28a His6-SpyCatcher-mi3 gene (Addgene) was transformed into BL21 (DE3)-RIPL 
E.coli (Agilent). Single colonies were picked and inoculated into an LB overnight starter culture, 
and grown in 1L LB media until OD 0.8 (A600 nm) with shaking at 220 rpm at 37˚C, after which 
they were induced with 0.5 mM IPTG and grown for 16-20 hours at 20˚C. Cultures were then 
harvested and pellets were frozen in lysis buffer (250 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 
mM imidazole, 0.02% NaN3). For producing NPs for conjugation, pellets were thawed and lysed 
with a cell disruptor in the presence of 2.0 mM PMSF (Sigma), and the lysate was spun at 
21,000xg for 30 min, filtered with a 0.2 µm filter, and NPs were isolated by Ni-NTA 
chromatography using a prepacked HisTrapTM HP column (GE Healthcare), and eluting with 2.0 
M imidazole, 20 mM Tris-HCl pH 8, 150 mM NaCl, 0.02% NaN3. Eluted NPs were concentrated 
using an Amicon Ultra 15 mL 30K concentrator (MilliporeSigma) and further purified by SEC 
using a HiLoad® 16/600 Superdex® 200 (GE Healthcare) column equilibrated with 25 mM Tris-
HCl pH 8.0, 150 mM NaCl, 0.02% NaN3. NPs were then stored at 4°C and used for up to 1 
month for conjugations. SpyCatcher-NPs precipitated out of solution over time, and before use 
for conjugations, they were either filtered with a 0.2 µm filter or spun down at 21,000g for 10 
min. 
 
Preparation of HA-VLPs and HA-NPs. Purified SpyCatcher-VLPs or SpyCatcher-NPs were 
incubated with a 1.2-fold molar excess (HA protomer to VLP or NP subunit) of purified 
SpyTagged HA (either a single HA for making homotypic particles or an equimolar mixture of 
two or more HAs for making mosaic particles) at room temperature in TBS (25 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.02% NaN3) overnight. Conjugated VLPs or NPs were then separated from 
free HA trimers by SEC on a Superose 6 10/300 (GE Healthcare) column equilibrated with PBS 
(20 mM sodium phosphate pH 7.5, 150 mM NaCl). Fractions corresponding to conjugated VLPS 
or NPs were collected and analyzed via SDS-PAGE. Concentrations were determined using a 
Bio-Rad Protein Assay. For stability studies, mosaic-NP preps were stored for a month at 4°C 
and then analyzed via SEC using a Superose 6 10/300 (GE Healthcare) column equilibrated 
with PBS (20 mM sodium phosphate pH 7.5, 150 mM NaCl). 
 
EM. HA-conjugated and unconjugated VLPs and NPs were compared by negative-stain EM. 
Ultrathin, holey carbon-coated, 400 mesh Cu grids (Ted Pella, Inc.) were glow discharged for 60 
s at 15 mA. A 3-µl aliquot of SEC-purified HA-VLPs and HA-NPs diluted to approximately 40-
100 ug/ml were applied to the grids for 60 s, and then negatively stained with 2% (w/v) uranyl 
acetate for 30 s. Data were collected with a FEI Tecnai T12 transmission electron microscope at 
120 keV at 42,000x magnification. 
 
SEC-purified HA-VLPs and HA-NPs were prepared on grids for cryo-ET using a Mark IV 
Vitrobot (ThermoFisher Scientific) operated at 21°C and 100% humidity. 3.1 μL of sample was 
mixed with 1 μL of 10 nm colloidal gold beads (Sigma-Aldrich) as fiducial markers and then 
applied to 300 mesh Quantifoil R2/2 grids, blotted for 3.5 s, and plunge-frozen in liquid ethane 
surrounded by liquid nitrogen. Cryo-ET was performed on a 300kV Titan Krios transmission 
electron microscope (ThermoFisher Scientific) equipped with a Gatan energy filter (slit width 20 
eV) operating at a nominal 33,000x magnification. For HA-VLPs, tilt series were collected on a 
K2 direct electron detector (Gatan) with a pixel size of 2.23 Å•pixel-1 using SerialEM software  
[27], a  -3 to -6 µm defocus range, and a total of 98 e-•Å-2 per tilt series. For HA-NPs, tilt series 
were recorded in counting mode on a K3 direct electron detector (Gatan) with a pixel size of 
2.68 Å•pixel-1 using SerialEM [27], a -4 to -5 μm defocus range, and a total dose of ~140 e-•Å-2 
per tilt series. For both data collections, tilt series images were collected using a dose-
symmetric tilt scheme [28] ranging from -60° to 60° with 2° and 3° intervals for HA-VLPs and 
HA-NPs, respectively. Images were aligned and reconstructed using IMOD [29, 30].  
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Immunizations. All animal experiments were carried out in 4-6 week old female Balb/c mice 
obtained from Charles River Laboratories. Immunizations for HA-VLPS and HA-NPs were done 
in Balb/c mice (n=4 in each group) through intraperitoneal (ip) injections,of 20 ug of antigen in 
200 µL of 50% v/v of adjuvant (Sigma Adjuvant System®). For experiments in Figure 4A, mice 
were immunized on Day 0 and boosted on Day 14. Animals were bled weekly via tail veins. For 
animals in Figure 5 A, mice were also boosted on Day 37. Mice were then euthanized 2 weeks 
later (Day 49, 51), bled through cardiac puncture, and spleens were harvested. All blood 
samples were allowed to clot at room temperature in MiniCollect® Serum and Plasma Tubes 
(Greiner), and then serum was harvested, frozen in liquid nitrogen, and stored at -80˚C until 
use. All animal procedures and experiments were performed according to protocols approved 
by the IACUC. 
 
ELISAs. Nunc® MaxiSorp™ 384-well plates (Sigma) were coated with 10 µg/ml of a purified HA 
(without a SpyTag) in 0.1 M NaHC03 pH 9.8 and stored overnight at 4oC. Plates were then 
blocked with 3% bovine serum albumin (BSA) in TBS-T (TBS with 0.1% Tween 20) for 1 hr at 
room temperature. Plates were washed with TBS-T after each step. Serum was diluted 1:100 
and then serially diluted by 4-fold with TBS-T/3% BSA and added for 3 hr at room temperature. 
A 1:50,000 dilution of secondary HRP-conjugated goat anti-mouse IgG (Abcam) was added for 
1 hr at room temperature. Plates were developed using SuperSignal™ ELISA Femto Maximum 
Sensitivity Substrate (ThermoFisher) and read at 425 nm. Curves were plotted and integrated to 
obtain the area under the curve (AUC) using Graphpad Prism 8.3. 
 
In vitro neutralization assays. Neutralization assays were conducted using live PB1flank-
eGFP virus for BSL 2 strains A/Aichi/02/1968 (X31; H3N2), A/California/04/2009 (CA09; H1N1), 
A/Texas/36/1991 (TX91; H1N1), and A/Wisconsin/67/2005 (WI05; H3N2) as described [31] 
using reagents kindly provided by Dr. Jesse Bloom (Fred Hutchinson). Plasma was set at a top 
dilution of 1:200 (for Figure 4C) or 1:100 (For Figure 5C) and serially diluted 5-fold (for Figure 
4C) or 4-fold (For Figure 5C) for a total of 8 dilutions. Pseudovirus assays were conducted as 
described [32] for BSL 3 strains A/Shanghai/1/2013 (SH13; H7), A/Jiangxi-Donghu/346/2013 
(JX346; H10), A/Vietnam/1203/ 2004 (Viet04; H5N1), and A/Japan/305/1957 (JP57; H2N2). 
Plasma was set at a top dilution of 1:200 (for Figure 4C) or 1:100 (For Figure 5C) and serially 
diluted 4-fold for a total of 8 dilutions. Neutralization data were plotted, curves were fit, and ID50 
values were calculated using Antibody Database [33]. Reported IC50s are geometric means, 
which are suitable for data sets covering multiple orders of magnitude [34].  
 
Flow cytometry. 
Single cell suspension were prepared from immunized mouse spleens by mechanical 
dissociation using the back of a syringe plunger. Cell suspensions in 70 µm cell strainers were 
washed in cold RPMI 1640 media and treated with ACK lysing buffer (Gibco) to lyse red blood 
cells. The resulting white blood cell preparation was resuspended in RPMI 1640 MACS and 
enriched for memory B cells using the negative selection portion of the protocol in a mouse 
Memory B Cell Isolation Kit (Miltenyi). Enriched splenocytes were then stained with the following 
monoclonal antibodies and reagents: CD4-APC-eFluor 780 (clone: RM4-5), F4/80-APC-eFluor 
780 (clone: BM8), CD8a-APC-eFluor 780 (clone: 53-6.7), Ly-6G-APC-eFluor 780 (clone: RB6-
8C5), IgM-PerCP-eFluor 710 ( clone: II/41) (eBioscience), CD19-FITC (clone: 6D5) (Biolegend), 
IgG1 BV421 (clone: X40), IgG2 BV421 (clone: R19-15) (BD Bioscience), and CA09-HA-APC, 
Aichi-HA-PEeflour610 and Viet04-HA-PE (prepared as described above). Cell viability was 
analyzed with Ghost Dye™ Violet 510 (Tonbo). Splenocytes were incubated for 30 min at 4oC in 
the dark and then washed twice with staining buffer (HBSS, 50 mM HEPES pH 7.4, 2.5 mg/ml 
BSA, 50 ug/ml DNAse, 1 mM MgCl2). Stained cells were then analyzed with a SY3200 Cell 
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Sorter (Sony) configured to detect 9 fluorochromes. 500,000-1,000,000 events were collected 
per sample and analyzed via FlowJo software (TreeStar).  
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Figure 1. Design and characterization of SpyTagged HAs, SpyCatcher VLPs, and 
SpyCatcher-NPs. A. Top: Schematic of the SpyTagged HA construct (SP = signal peptide). 
The HA2 ectodomain is followed by a foldon trimerization domain from T4 fibritin, a 13-residue 
SpyTag, and a 6x-His tag. Amino acids are numbered according to the H3 nomenclature. 
Horizontal lines represent Gly4Ser linkers. Bottom: Surface representation of an HA trimer 
structure (PDB 3VUN), schematic of a SpyTagged HA, and list of influenza strains from which 
SpyTagged HAs were derived. B. SEC profiles and reducing SDS-PAGE analysis of 8 different 
purified SpyTagged HAs including the Y98F substitution. C. SpyCatcher-AP205 VLPs. Top: 
Schematic of construct. Bottom: EM structure of T=3 AP205 particle (PDB 5FS3) [24] with the 
locations of SpyCatcher fusion sites indicated by red dots (left) and schematic SpyCatcher-VLP 
(right). D. Purification of SpyCatcher-VLPs. Left: SEC profile with peak representing properly-
assembled VLPs indicated. Right: Reducing and non-reducing SDS-PAGE of fractions 
corresponding to VLP peak. E. SpyCatcher-mi3 NPs. Top: schematic of construct. Bottom: EM 
structure of I3-01 particle related to mi3 [25] with the locations of SpyCatcher fusion sites 
indicated by red dots (left) and schematic SpyCatcher-NP (right). F. Purification of SpyCatcher-
NPs. Left: SEC profile. Right: Reducing SDS-PAGE of fractions corresponding to mi3 NP peak. 
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Figure 2. Conjugation of SpyCatcher-VLPs and -NPs. A. SpyCatcher-AP205-VLP 
conjugations with SpyTagged-HA trimers. B. Purification of conjugated SpyCatcher-VLPs. Left: 
SEC separation of conjugated VLPs from free HA trimers. Right: Reducing SDS-PAGE analysis 
of VLPs and purified HAs. C. SpyCatcher-mi3-NP conjugations with SpyTagged-HA Y98F 
mutant trimers. D. Purification of homotypic SpyCatcher-NPs. Left: SEC separation of 
conjugated NPs from free HA trimers. Right: Reducing SDS-PAGE analysis of NPs and purified 
HAs. E. Purification of heterotypic mosaic-NPs. Left: SEC separation of conjugated NPs from 
free HA trimers, including SEC profile of purified conjugated NPs after 1 month storage at 4 ˚C. 
Right: Reducing SDS-PAGE analysis of NPs and purified HAs.  
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Figure 3. EM of conjugated VLPs and NPs. Scale bars shown apply to all images in each 
panel. A. Negative-stain EM of HA-conjugated VLPs and mi3 NPs compared with unconjugated 
counterparts. B. Cryo-EM micrograph of HA-VLP sample (left) and representative 2D class 
averages (right). Densities for HA trimers are blurry in the class averages, likely because the 
trimers occupy different positions on individual particles. C. Cryo-ET imaging of HA particles. 
Computationally-derived tomographic slices of HA-VLP (top panels; 2.78 nm slices) and HA-NP 
(bottom panels; 3.21 nm slices). Slices derived from the widest portions of representative 
particles are shown to the right in each panel.  
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Figure 4. Immunizations with HA-VLPs. A. Schematic of the immunization protocol (four 
animals per injection). B. Serum antibody response to HA shown by ELISA binding as area 
under the curve (AUC) of Day 28 serum to Group 1 and Group 2 HA trimers. Each dot 
represents serum from one animal, with arithmetic means and standard deviations represented 
by rectangles and horizontal lines, respectively. Homotypic strains (present on the mosaic-2 
VLP) and heterotypic strains (not present on the mosaic-2 VLP) are indicated by the blue and 
red rectangles, respectively, above the ELISA data. Bottom right: Color coding for data. C. 
Serum neutralization titers from Day 45 determined by in vitro neutralization assays using live 
virus or pseudoviruses. Each dot represents serum from one animal, with geometric mean and 
geometric standard deviations represented by rectangles and horizontal lines, respectively. 
Dotted lines indicate limits of detection. 
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Figure 5. Immunizations with HA-NPs. A. Schematic of the immunization protocol (four 
animals per injection). B. Serum antibody response to HA shown by ELISA binding as area 
under the curve (AUC) of Day 21 and Day 49 serum to recombinant Group 1 and Group 2 HA 
trimers. Each dot represents serum from one animal, with means and standard deviations 
represented by rectangles and horizontal lines, respectively. Homotypic strains that were 
present on the mosaic NPs and heterotypic strains that were not present are indicated by the 
blue and red rectangles, respectively, above the ELISA data. Top right: Color coding for data. C. 
Serum neutralization titers from Day 45 determined by in vitro neutralization assays using live 
virus or pseudoviruses. Each dot represents serum from one animal, with geometric means and 
geometric standard deviations represented by rectangles and horizontal lines, respectively. 
Dotted lines indicate limits of detection. Top right: Color coding for data. 
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Figure 6. B cell responses induced by mosaic NP immunizations. A. Gating strategy for 
flow cytometry experiments using single cell suspension from spleens harvested from 
immunized mice in Figure 5A. Anti-CD3, anti-CD8, anti-F4/80, and anti-Ly6G were used to 
remove T cells, macrophages, monocytes, and neutrophils. Cells were then gated to isolate 
CD19/IgG-positive and IgM-negative, which were probed for binding of CA09-HA-APC 
(allophycocyanin), Aichi-HA-PE-eFluor610 (phycoerythrin-eFluor 610), and/or Viet04-HA-PE 
(phycoerythrin). B. Percent CA09+, Viet04+, Aichi+, and CA09+/Viet04+ in IgG+ B cells plotted 
for each group.  
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